Safety and Effectiveness of Dimethyl Fumarate in Japanese Patients With Multiple Sclerosis: Subgroup Analysis of Older Patients and Patients Switching From Fingolimod or Natalizumab Using 2‐Year Post‐Marketing Surveillance Data

Clinical and Experimental Neuroimmunology · Published 2026-08-01 · DOI 10.1111/cen3.70074

Free full text

Authors (11)

Ichiro Nakashima, Toshiyuki Fukazawa, Kazumasa Yokoyama, Takashi Yamamura, Hirofumi Ochi, Michihiro Kanda, Yayoi Sato, Ryusuke Sato, Haruki Makioka, Aya Tsuchiya, Takahiko Saida

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Nakashima, I., Fukazawa, T., Yokoyama, K., et al. (2026). Safety and Effectiveness of Dimethyl Fumarate in Japanese Patients With Multiple Sclerosis: Subgroup Analysis of Older Patients and Patients Switching From Fingolimod or Natalizumab Using 2‐Year Post‐Marketing Surveillance Data. Clinical and Experimental Neuroimmunology. https://doi.org/10.1111/cen3.70074

Related articles